STOCK TITAN

T. Rowe Price (NASDAQ: DYN) lists 26,578,437 shares, a 16.2% stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Dyne Therapeutics reports a Schedule 13G/A from T. Rowe Price Investment Management showing beneficial ownership of 26,578,437 shares of common stock, representing 16.2% of the class.

The filing shows sole voting power for 26,223,470 shares and sole dispositive power for 26,578,437. The filing includes a statement denying beneficial ownership by T. Rowe Price Investment Management. The form is signed by Ellen York on 03/06/2026.

Positive

  • None.

Negative

  • None.

Insights

T. Rowe Price reports a substantial passive stake in Dyne Therapeutics at 16.2%.

The filing lists 26,578,437 shares beneficially owned with 26,223,470 shares of sole voting power as of the amendment date. The filer also includes an explicit denial of beneficial ownership in the text.

Institutional filings like this commonly reflect investment management positions; the exact economic interest attribution is subject to the filer’s reservation language. Subsequent filings or disclosures could clarify voting or investment authority.






02/28/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:03/06/2026

FAQ

What does the T. Rowe Price 13G/A filing for DYN mean?

It reports that T. Rowe Price Investment Management holds 26,578,437 shares of Dyne common stock, equal to 16.2% of the class. The filing documents voting and dispositive power and includes a denial of beneficial ownership by the filer.

How many Dyne shares does T. Rowe Price have voting power over?

The filing shows sole voting power over 26,223,470 shares. It lists 0 shared voting power and cites sole dispositive power over 26,578,437 shares.

Does the filing prove T. Rowe Price is the beneficial owner of DYN shares?

No; the filing includes an explicit statement in which T. Rowe Price Investment Management "expressly denied" beneficial ownership. The form still reports amounts and voting/dispositive powers as required by SEC rules.

When was the Schedule 13G/A signed and filed for DYN?

The signature block shows the filing was signed by Ellen York, Vice President, on 03/06/2026. The cover line references the relevant record date of 02/28/2026.
Dyne Therapeutics, Inc.

NASDAQ:DYN

View DYN Stock Overview

DYN Rankings

DYN Latest News

DYN Latest SEC Filings

DYN Stock Data

2.45B
151.43M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM